Last updated 8 months ago
Epicardial Cardiac Fat-CT (EPIC-CT)
136 patients around the world
Available in Mexico
This randomized, open-label clinical trial will assess the effects of dapagliflozin compared to semaglutide on epicardial fat in patients with ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction over a 12-month period. Epicardial fat will be measured by simple coronary tomography during initial hospitalization for infarction and after 12 months of treatment with both medications.
It will include patients over 18 years old with STEMI and NSTEMI, with or without a diagnosis of type 2 diabetes and clinical obesity. Patients will be discharged following treatment guidelines, and their adherence to medication and tolerability will be monitored.
Instituto Mexicano del Seguro Social
1Research sites
136Patients around the world
This study is for people with
Coronary heart disease
Acute myocardial infarction
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Criteria for the fourth definition of acute myocardial infarction with and without ST-segment elevation.Diagnosed with type 2 diabetes.Initial serum high-sensitivity CRP value > 2.0 mg/L.Clinically obese.LVEF >50%.
- Patients who have recently received immunosuppressive therapy.Patients with a history of ischemic heart disease.Known allergy to any of the medications used.Use of any of the study drugs more than 6 months prior to randomization.Patients experiencing diabetic ketoacidosis.Patients with hemodynamic instability (mean arterial pressure <60 mmHg while on vasopressors).Pregnant women.Patients with a history or current diagnosis of cancer.Patients with documented active infections, such as pneumonia or urinary tract infections.Patients with pancreatitis.
Sites
Hospital Regional de Alta Especialidad del Bajío
Recruiting
StudyEPIC-CT
SponsorInstituto Mexicano del Seguro Social
Study typeInterventional
Conditions
Acute myocardial infarction
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07297589
